Dyslipidemia
📧 Sign up to get email alerts when something new happens for Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-05-04FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for atorvastatin calcium, authorizing the atorvastatin calcium product unde…
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension [Phase 4]
Phase 4 trial evaluating Duowell® versus telmisartan monotherapy in patients with mild dyslipidemia and hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides [Phase 2]
Phase 2 trial update for ETC-1002 evaluating efficacy and safety in dyslipidemia with variable triglyceride levels; results posted after com…
-
CLINICAL_TRIALS withdrawal · 2021-02-24Clinical Trial Update: Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia. [Phase 3]
Phase 3 trial of a fixed-dose combination of valsartan and rosuvastatin was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets [Phase 4]
Phase 4 clinical trial evaluating benefits of starting at various atorvastatin doses to achieve cholesterol targets.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients. [Phase 4]
Phase 4 trial evaluating the COACH program for management of dyslipidemia; study completed.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST) [Phase 4]
Phase 4 trial evaluating different starting doses of atorvastatin to achieve cholesterol targets.
-
FDA approval · 2021-02-02FDA Approved: FENOFIBRATE — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for fenofibrate submitted by Solco Healthcare US, LLC.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia [Phase 3]
Open-label phase 3 trial evaluating the combination of amlodipine and atorvastatin in subjects with hypertension and dyslipidemia has comple…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population [Phase 4]
Phase 4 trial update evaluating Caduet's ability to achieve blood pressure and lipid endpoints in adults with hypertension and dyslipidemia.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Caduet in an Untreated Subject Population [Phase 4]
Phase 4 trial update for Caduet in untreated subjects showing completed status.
-
FDA approval · 2020-12-10FDA Approved: LOPID — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Lopid (gemfibrozil) submitted by Parke-Davis Div of Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2020-07-21Clinical Trial Update: Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia [Phase 3]
Phase 3 trial assessing safety, tolerability, and LDL-C reduction with evolocumab in HIV patients with hyperlipidemia/mixed dyslipidemia; co…
-
FDA approval · 2020-06-12FDA Approved: FENOFIBRATE — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's fenofibrate Original Application (ANDA213864), authorizing a generic fenofibrate product. This marks an appro…
-
CLINICAL_TRIALS trial_result · 2020-03-24Clinical Trial Update: 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia [Phase 2, Phase 3]
12-month open-label extension study of LCP-AtorFen in dyslipidemia completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia [Phase 2]
Phase 2 trial assessing an atorvastatin/fenofibrate combination (LCP-AtorFen) for dyslipidemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-22Clinical Trial Update: Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia [Phase 3]
Phase 3 trial evaluating rosuvastatin plus ezetimibe in high-risk patients with primary hypercholesterolemia or mixed dyslipidemia has compl…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) [Phase 2]
Phase 2 trial assessing RO4607381 in patients with relatively low HDL-cholesterol completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-12-17Clinical Trial Update: Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women [Phase 2]
Phase 2 trial examining worksite wellness interventions and their effects on vascular function, insulin sensitivity, and HDL in overweight o…
-
FDA approval · 2019-12-09FDA Approved: FENOFIBRATE — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application for fenofibrate (generic) under ANDA 202252.
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451 [Phase 3]
Phase 3 clinical trial update evaluating DWJ1451 for hypertension and dyslipidemia.
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia [Phase 3]
Phase 3 trial evaluating the efficacy and safety of a combination treatment of fimasartan and atorvastatin in essential hypertension with dy…
-
CLINICAL_TRIALS research · 2019-10-15Clinical Trial Update: Effects of Metformin on Hepatic FFA Metabolism [Phase 4]
Phase 4 clinical trial evaluating the effects of metformin on hepatic free fatty acid metabolism in adults with type 2 diabetes and dyslipid…
-
CLINICAL_TRIALS trial_result · 2019-10-03Clinical Trial Update: Vascular Lifestyle-Intervention and Screening in Pharmacy [NA]
Clinical trial update for a vascular lifestyle-intervention and screening study; status and results not clearly disclosed in the snippet.
-
FDA approval · 2019-09-23FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fenofibrate (generic). This action grants an additional approval to the AND…